Daniel Carlson: Hey guys. I’m just a couple of follow-up questions here regarding INKmune. And I just saw that Amgen pulled a drug from clinical trials yesterday in prostate and wrote down about $600 million. I was wondering if you could comment on, how that impacts, your thinking about your program at all if at all.
Mark Lowdell: Yeah. I have a stab at that. I think you most as I said just now. I don’t think T cells immediately are the answer in prostate cancer and the anti-T47, antibody you’re talking about is a good example of that. And the checkpoint inhibitor somewhat the anti-CD3 combination of antibodies work, so I think we need to look at — excuse me — we need to look at activating cells are actually there. And so it just makes me more enthusiastic about the prospects where it need.
Daniel Carlson: Great. And that’s what I thought, thanks. Thanks mark. And then a question about them rep missed their top line yesterday as well. I know there is leader in DMD, is this something that you think might push them towards working with you guys or how do you see that items following [Indiscernible].
RJ Tesi: David?
David Moss: You’re asking me to guess what corrupt is going on. I can tell you; they’re going through probably pipeline reorganization. I think that you recently had a steroid that was approved that supposed to be a slightly better steroid than the current standard of care. As I spoke about earlier we believe that XPro going down a completely different pathway than where steroids, than what steroids pathway provides significant benefit over a lot of the problems that we are that are associated with steroids. DMD is really an interesting space, because the Exon-Skipping drugs all have confirmation trials which are still ongoing there kind of along that been taken a long time while they keep these drugs on the market. It’s going to be interesting to see what the FDA does with the fact that the confirmation trial for the Gene Therapy that Sarepta ran it failed.
And there’s some thought on the street that they keep the market keep the program on the market. I don’t know what’s going to happen. My guess is with what the FDA’s done with regard to that program have been wrong. So I wouldn’t hold any of that water. But the bottom-line is that we feel that there needs to be a new approach to DMD beyond Exon-Skipping, beyond steroids and beyond Gene Therapy. And we think that the DN-TNF is a really creative approach. We like it a lot.
Daniel Carlson: Thanks. Thanks David. That’s it for me guys. All my other questions were asked already. So thank you.
Operator: Thank you very much. Ladies and gentlemen, we have reached the end of the question-and-answer session. And I’d like to turn the call back to RJ, for closing remarks. Thank you, sir.
RJ Tesi: So thank you. INmune Bio has making progress on two-fronts. Each of our platforms have had a significant increase in shall we say profile and then last quarter. With XPro we hope to have a therapy that stops the progression of cognitive client in patients with ADI with Alzheimer’s Disease, that’s very different than what is offered patients today. With INKmune in Metastatic Castration-Resistant Prostate Cancer, we hope to control a disease that in many men can be quiet and indolent. But in many is lethal. We are confident in these ambitious goals. We thank you for your attention today and to those of you that are shareholders, we thank you for your continuing support. With that, have a good day.
Operator: Thank you. This concludes today’s conference. You may disconnect your lines at this time. And thank you very much for your participation.
